NEJM Clinician: Are PPIs Linked to COPD Flares?

Why It Matters

Unwarranted long‑term PPI use may double COPD flare risk, prompting clinicians to reevaluate prescriptions and improve patient outcomes.

Key Takeaways

• Long‑term PPI use linked to nearly double COPD exacerbations
• Risk escalates with cumulative duration of proton‑pump inhibitor exposure
• Study analyzed >900,000 obstructive airway patients using claims data
• Association persists after adjusting for age, comorbidities, prior flares
• Clinicians should reassess necessity and dosage of PPIs in COPD patients

Summary

The NEJM Clinician video examines whether proton‑pump inhibitors (PPIs) contribute to increased COPD flare‑ups. It highlights a recent claims‑based analysis of more than 900,000 patients with obstructive airway disease, comparing those prescribed PPIs to those who were not, while controlling for age, comorbidities and prior exacerbations.

The investigators found that patients on PPIs experienced almost twice the number of respiratory exacerbations, and the risk grew proportionally with longer cumulative exposure. Even after rigorous adjustment for confounding variables, the association remained statistically significant, suggesting a potential dose‑response relationship.

The presenter cautions that the findings do not prove causation; residual confounding is possible. However, the proposed mechanism—alterations in the gut microbiome affecting lung immunity—offers a plausible biological link. He urges clinicians to review long‑standing PPI prescriptions in COPD patients, confirming ongoing indication, minimizing dose, and planning step‑down or discontinuation when feasible.

If clinicians act on this insight, unnecessary PPI exposure could be reduced, potentially lowering COPD exacerbation rates and associated healthcare costs. The discussion underscores the broader need for periodic medication reconciliation, especially for drugs that become entrenched without reassessment.

Original Description

NEJM Clinician Editor-in-Chief Raja-Elie Abdulnour, MD, explains a retrospective study investigating if proton pump inhibitor (PPI) use is associated with exacerbations of chronic obstructive airway diseases. Read the full summary at clinician.nejm.org.